These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7700900)

  • 1. Ribozyme mediated therapy for chronic myelogenous leukemia.
    Leopold LH; Shore SK; Newkirk T; Mangan K; Reddy EP
    Prog Clin Biol Res; 1994; 389():175-82. PubMed ID: 7700900
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y; Chen YZ; Huang HF; Chen P; Lu LH
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular approaches to purging of chronic myelogenous leukemia marrow in autologous transplantation.
    Yuan T; Zhou YQ; Herst CV; Reading C; Ellersen D; Etkin M; Khouri I; Kantarjian H; Talpaz M; Deisseroth A
    Prog Clin Biol Res; 1992; 377():227-30. PubMed ID: 1438419
    [No Abstract]   [Full Text] [Related]  

  • 5. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L; Wilson SB; Milliken S; Biggs J; Kearney P
    Exp Hematol; 1993 Dec; 21(13):1714-8. PubMed ID: 8243570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of BCR/ABL-negative progenitor cells from chronic myeloid leukemia marrow.
    Leemhuis T; Leibowitz D; Cox G; Srour EF; Tricot G; Hoffman R
    Prog Clin Biol Res; 1992; 377():231-7. PubMed ID: 1279706
    [No Abstract]   [Full Text] [Related]  

  • 8. Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
    Leopold LH; Shore SK; Newkirk TA; Reddy RM; Reddy EP
    Blood; 1995 Apr; 85(8):2162-70. PubMed ID: 7718886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
    Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of detection of BCR/ABL transcript after allogeneic and autologous transplant.
    Saglio G; Guerrasio A; Gottardi E; Parziale A; Martinelli G; Zaccaria A; Frassoni F
    Bone Marrow Transplant; 1994; 14 Suppl 3():S62-7. PubMed ID: 7697012
    [No Abstract]   [Full Text] [Related]  

  • 12. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W
    Klin Padiatr; 1995; 207(4):222-4. PubMed ID: 7564157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK; Nabissa PM; Reddy EP
    Oncogene; 1993 Nov; 8(11):3183-8. PubMed ID: 8414522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity of ribozymes against the bcr-abl mRNAs in vitro.
    James HA; Twomey CM; Mills KI; Gibson I
    Biochem Soc Trans; 1996 Aug; 24(3):409S. PubMed ID: 8878953
    [No Abstract]   [Full Text] [Related]  

  • 15. Oncogene inactivation in a mouse model.
    Tanabe T; Kuwabara T; Warashina M; Tani K; Taira K; Asano S
    Nature; 2000 Aug; 406(6795):473-4. PubMed ID: 10952298
    [No Abstract]   [Full Text] [Related]  

  • 16. Multi-unit anti-BCR-ABL ribozyme therapy in chronic myelogenous leukemia.
    Leopold LH; Shore SK; Reddy EP
    Leuk Lymphoma; 1996 Aug; 22(5-6):365-73. PubMed ID: 8882949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
    Maki G; Tam YK; Berkahn L; Klingemann HG
    Bone Marrow Transplant; 2003 Jun; 31(12):1119-25. PubMed ID: 12796791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
    Snyder DS; Wu Y; Wang JL; Rossi JJ; Swiderski P; Kaplan BE; Forman SJ
    Blood; 1993 Jul; 82(2):600-5. PubMed ID: 8329715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA.
    Lange W; Cantin EM; Finke J; Dölken G
    Leukemia; 1993 Nov; 7(11):1786-94. PubMed ID: 8231247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
    Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
    Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.